Taiwanese drugmaker TaiGen Biotechnology has announced that it has signed an exclusive licensing agreement with Luminarie Canada to develop and commercialize Taigexyn (nemonoxacin) in Canada, Australia and New Zealand.
Taigexyn is a new antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria.
Under the terms of the agreement, Luminarie will be responsible for the development, registration and commercialization of Taigexyn in the three countries and assume all associated costs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze